IBI-356 / Innovent Biologics - LARVOL DELTA

A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (clinicaltrials.gov) - P1 | N=99 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Aug 2025

Trial completion • Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (clinicaltrials.gov) - P1 | N=99 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2024 ➔ Aug 2025

Enrollment closed • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (clinicaltrials.gov) - P1 | N=98 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (clinicaltrials.gov) - P1 | N=98 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology